Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica LaboratoriesNSE:BMLL +1.21%18 10-Year ROIIC % is 0.00 as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 693 Medical Devices & Instruments companies, Bio Medica Laboratories ranks worse than 144300% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Bio Medica Laboratories does not have enough data to calculate 10-Year ROIIC %.
Bio Medica Laboratories (NSE:BMLL) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Bio Medica Laboratories 10-Year ROIIC % Related Terms
Bio Medica Laboratories 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories 10-Year ROIIC % Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
10-Year ROIIC %
0.00
0.00
0.00
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
10-Year ROIIC %
0.00
0.00
0.00
NSE:BMLL vs ISRG, BDX, MDLN: 10-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's 10-Year ROIIC % falls into.
Bio Medica Laboratories 10-Year ROIIC % Calculation
Bio Medica Laboratories's 10-Year ROIIC % for the quarter that ended in Mar. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 107.0794869 (Mar. 2025) - (Mar. 2015) )
/
( 339.391 (Mar. 2025) - (Mar. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Bio Medica Laboratories (NSE:BMLL) has a 10-Year ROIIC % of 0.00 as of Mar. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Bio Medica Laboratories and its competitors. According to the industry distribution chart, Bio Medica Laboratories ranks #999999 out of 693 companies in the Medical Devices & Instruments industry.
Is Bio Medica Laboratories' 10-Year ROIIC % too high?
Bio Medica Laboratories' current 10-Year ROIIC % is 0.00. Based on the distribution chart, Bio Medica Laboratories ranks #999999 out of 693 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' 10-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #999999 out of 693 companies for 10-Year ROIIC %. This places Bio Medica Laboratories in the lower half of its industry. The industry median 10-Year ROIIC % is 2.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.31, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current 10-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current 10-Year ROIIC % of 0.00. The current 10-Year ROIIC % is 0.00. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current 10-Year ROIIC % is 0.00 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
